Search for: "Tom Lamb" Results 1 - 20 of 931
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Feb 2009, 8:50 am
Discusses The Dire Consequences Of Fraudulent Science, Federal Preemption, And Corporate Deregulation (Posted by Tom Lamb at DrugInjuryWatch.com) Thomas O. [read post]
8 Aug 2008, 7:09 pm
Study Published In Stroke Shows Risk Not Increased With Celebrex Nor With Other Medications  In NSAIDs Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com) An article in the July 2008 edition of the medical journal Stroke  reports that the COX-2 inhibitors Bextra (valdecoxib) and Vioxx (rofecoxib) significantly  increase the risk of cerebrovascular events, commonly referred to as strokes, whereas another COX-2 drug, Celebrex (celecoxib),… [read post]
8 Feb 2010, 12:29 pm by Tom Lamb
Authors Suggest That Certain Patients Starting Januvia Should Have Their Liver Function Monitored (Posted by Tom Lamb at DrugInjuryWatch.com) In the recent past we considered whether Januvia (sitagliptin) can cause pancreatitis in patients using this relatively new diabetes medication. [read post]
21 Apr 2008, 12:39 pm
This Condition Is Referred To Generally As Bisphosphonate-Related Osteonecrosis Of The Jaw (BRONJ) (Posted by Tom Lamb at DrugInjuryWatch.com) The April 8, 2008 edition of Journal Watch General Medicine included a brief article titled "Should We Be Concerned About Jaw Osteonecrosis with Oral Bisphosphonates? [read post]
6 Mar 2008, 11:14 am
" (Posted by Tom Lamb at DrugInjuryWatch.com) In his March 5, 2008 article -- "Medical device safety in spotlight; M.D. uses Medtronic recall in critique of FDA, manufacturers" -- reporter Christopher Snowbeck explores how the Sprint Fidelis lead wire recall in October 2007 by Medtronic Inc. showed the medical device safety system as it currently operates here in the U.S. is fundamentally flawed. [read post]
3 Jul 2008, 7:20 pm
Tom Lamb at Drug Injury Watch has written about the spate of lawsuits filed in Sprint Fidelis cases, and Medtronic's potential defense, based on the recent Reigel decision. [read post]
30 May 2007, 10:29 am
Patrick Lamb and Tom Kane comment on "The Way of the Mastodon", by Sun Microsystems General Counsel Mike Dillon. [read post]
1 May 2007, 2:42 pm
Covers Procrit, Aranesp & Epogen, As Well As Adderall, Ambien, And More (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's Patient Safety News (PSN) is a series of monthly video news shows intended primarily for doctors and other health care professionals. [read post]
4 Sep 2007, 9:03 am
Drug Safety Update Publishes September 2007 Guide For Doctors To Assess HRT Risks And Benefits (Posted by Tom Lamb at DrugInjuryWatch.com) The second issue of Drug Safety Update, an electronic bulletin (PDF file) published by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), was published on September 3, 2007. [read post]
9 Dec 2007, 9:06 pm
Covers Sprint Fidelis Cardiac Leads, Byetta, And Bisphosphonates Such As Fosamax (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's Patient Safety News (PSN) is a series of monthly video news shows intended primarily for doctors and other health care professionals. [read post]
2 Apr 2009, 12:26 pm
Glitazone Class Of Diabetes Drugs Can Increase The Risk Of Bone Fractures And Diabetic Macular Edema (Posted by Tom Lamb at DrugInjuryWatch.com) In 2007 the FDA required a black-box warnings on the package insert, or label, of Avandia and Actos labels which states that these diabetes drugs should not be used in patients with advanced congestive heart failure (CHF). [read post]
18 Dec 2007, 2:16 pm
People With Hypertrophic Cardiomyopathy And Those With Defibrillator-Pacemaker Dual Unit Implants May Be More In Need Of Lead Wire Replacement After Medtronic Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As presented in a December 13, 2007 New York Times (NYT) article, "Patients Wonder Whether to Replace a Wire That Might Fail", for thousands of people the October 2007 Medtronic recall of its Sprint Fidelis lead wires has created confusion and doubt on… [read post]
7 Jan 2010, 5:52 am by John J. Cord
Tom Lamb and the Drug Injury Watch have a good article on the selective information given by Amylin Pharmaceuticals about their diabetes drug Byetta (co-marketed with Eli Lilly) to the media and their investors in October, 2009. [read post]
16 Apr 2008, 7:20 am
And, We Learn About More Of Merck's Vioxx Shenanigans -- Another Benefit Of Pharmaceutical Product Liability Litigation (Posted by Tom Lamb at DrugInjuryWatch.com) For the second time in as many weeks, it was the Johnson & Johnson (J&J) company blog that tipped us off that Ortho-McNeil is responding to an item from The New York Times by posting a letter on the Ortho Evra web site. [read post]
18 Sep 2009, 1:25 pm
Drug Industry Document Archive (DIDA) Adds Newly Released Wyeth Ghostwriting Documents In September 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) A September 18, 2009 article, "Medical Editors Push for Crackdown on Ghostwriting", published by The New York Times (NYT) provides a very good overview of how some big pharmaceutical companies have effectively turned scientific articles into marketing vehicles for their new drugs by means of industry-financed… [read post]
6 Aug 2009, 12:18 pm
North Carolina State Board Leads Way As Regards Reporting Of Pharmacy-Associated Medication Mistakes (Posted by Tom Lamb at DrugInjuryWatch.com) QJM is a long-established, leading general medical journal. [read post]
7 Apr 2008, 2:09 pm
New York Times Reporters Gardiner Harris and Alex Berenson Bring Attention To How This Emerging Legal Issue Would Affect Drug Injury Cases (Posted by Tom Lamb at DrugInjuryWatch.com) To our pleasant surprise, we saw lots of notice and reaction being given to the April 6, 2008 New York Times (NYT) article, "Drug Makers Near Old Goal: A Legal Shield", wherein Times reporters Gardiner Harris and Alex Berenson explore the concept of "federal… [read post]
9 Dec 2009, 8:14 pm
Lieutenant-General Sir Graham Lamb, a man who does not mince words as can [...] [read post]
5 Mar 2012, 1:05 pm by Tom Lamb
Prescriber Error, Impaired Renal Function, Patient Age, And Lack Of An Effective Reversal Agent Are Cited (Posted by Tom Lamb at DrugInjuryWatch.com) A Letter to The Editor, titled "Bleeding Risk with Dabigatran in the Frail Elderly" (subscription required), which appeared in the March 1, 2012 edition of the New England Journal of Medicine (NEJM) may help explain when and why there is a serious bleeding risk associated with Pradaxa (dabigatran). [read post]